Sickle Cell Disease Clinical Trial
Official title:
Pre-Transplant Immunosuppression and Related Haploidentical Hematopoietic Cell Transplantation for Patients With Severe Hemoglobinopathies
Verified date | November 2022 |
Source | M.D. Anderson Cancer Center |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
This clinical trial studies the effect of pre-transplant immunosuppression (PTIS) and donor stem cell transplant in treating patients with severe blood diseases (hemoglobinopathies). PTIS helps prepare the body for the transplant and lowers the risk of developing graft versus host disease (GVHD). Hematopoietic cells are found in the bone marrow and produce blood cells. Hematopoietic cell transplantation (HCT) injects healthy hematopoietic cells into the body to support blood cell production. PTIS and HCT may help to control severe hemoglobinopathies.
Status | Withdrawn |
Enrollment | 0 |
Est. completion date | December 5, 2022 |
Est. primary completion date | December 5, 2022 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 2 Years to 30 Years |
Eligibility | Inclusion Criteria: - Patients 2-30 years-of-age with confirmed sickle cell disease (SCD) (SS & sickle beta [SB]-thalassemia, both sickle beta 0 [SB0] and sickle beta plus [SB+]) or severe B-thalassemia major are potentially eligible - Patients with SCD should also meet the following eligibility criteria as outlined by the Center for Medicaid and Medicare Services: sickle cell disease and at least one of the following: - Stroke or neurological deficit lasting > 24 hours - Recurrent acute chest syndrome (ACS): 2 or more episodes of ACS in 2-year period preceding enrollment - Recurrent vaso-occlusive pain crises: 3 or more episodes per year in 2-year period preceding enrollment or recurrent priapism (3 or more episodes in the 2 years preceding enrollment) - Chronic transfusion program defined as 8 or more packed red blood cells (PRBC) transfusions per year to prevent central nervous system and/or vaso-occlusive complications in 1-year period preceding enrollment - Impaired neuropsychological function and abnormal cerebral magnetic resonance imaging (MRI) scan (silent strokes) - Stage I or II sickle lung disease - Sickle nephropathy (moderate or severe proteinuria or a glomerular filtration rate 30-50% of predicted normal value) - Bilateral proliferative retinopathy and major visual impairment in at least one eye - Osteonecrosis of multiple joints - Echocardiographic finding of tricuspid valve regurgitant jet velocity (TRJV) >= 2.7 m/sec - Patients with B-thalassemia are considered as severe if they are/have any of the following: - Transfusion-dependent - Evidence of extra-medullary hematopoiesis - Pesaro Class III - Patients shall not proceed to HCT without confirmation of primary diagnosis by review of available newborn screening results or hemoglobin electrophoresis and/or genetic testing - DONOR: High resolution HLA typing will be performed on all willing and available biologic parents and siblings without clinically significant hemoglobinopathy. Preference will be given to donors with the lowest number of HLA-allele mismatches - DONOR: Donor-specific anti-HLA antibodies will be obtained and analyzed from all patients. Preference will be given to donors with absent or low titer anti HLA-donor specific antibody levels when possible Exclusion Criteria: - Uncontrolled infection - Females who are pregnant and/or unwilling to cease breastfeeding - Seropositivity for human immunodeficiency virus (HIV) - Lansky or Karnofsky performance status < 70% - Life expectancy severely limited by concomitant illness - Uncontrolled arrhythmias or symptomatic cardiac disease - Uncontrolled symptomatic pulmonary disease - Evidence of chronic active hepatitis or cirrhosis - Serum conjugated (direct) bilirubin > 2 x upper limit of normal for age. Participants are not excluded if the serum conjugated (direct) bilirubin is > 2 x the upper limit of normal for age as per local laboratory and: - There is evidence of a hyperhemolytic reaction after a recent red blood cell (RBC) transfusion, OR - There is evidence of moderate direct hyperbilirubinemia defined as direct serum bilirubin < 5 times upper limit of normal (ULN) and not caused by underlying hepatic disease - Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) > 5 x upper limit of normal for age - Serum creatinine > 1.5 x upper limit of normal for age AND estimated or measure creatinine clearance < 70 mL/min/1.72 m^2 - Patient, parent or guardian unable/unwilling to provide consent and when indicated, assent - Patients with available HLA-matched related donor - Prior receipt of gene therapy - DONOR: All potential donors shall be tested by hemoglobin electrophoresis. Any potential donor with a clinically significant hemoglobinopathy will be deemed ineligible. Donors with sickle cell trait and beta thalassemia trait are eligible to donate |
Country | Name | City | State |
---|---|---|---|
n/a |
Lead Sponsor | Collaborator |
---|---|
M.D. Anderson Cancer Center |
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Event-free survival (EFS) | EFS is defined as survival time following HCT without a qualifying event. Will be summarized by the Kaplan-Meier method with 95% confidence intervals. | At 2 years post-hematopoietic cell transplantation (HCT) | |
Secondary | Event-free survival | EFS is defined as survival time following HCT without a qualifying event. Will be summarized by the Kaplan-Meier method with 95% confidence intervals. | Up to 100 days post-HCT | |
Secondary | Event-free survival | EFS is defined as survival time following HCT without a qualifying event. Will be summarized by the Kaplan-Meier method with 95% confidence intervals. | Up to 1 year post-HCT | |
Secondary | Overall survival | Will be summarized by the Kaplan-Meier method. | Up to 100 days post-HCT | |
Secondary | Overall survival | Will be summarized by the Kaplan-Meier method. | Up to 1 year post-HCT | |
Secondary | Transplant-related mortality | Will be summarized by the Kaplan-Meier method. | Up to 30 days post-HCT | |
Secondary | Time to platelet and neutrophil engraftment | Will be estimated using the method of Gooley et al. | Up to 2 years post-HCT | |
Secondary | Incidence of graft failure (primary and secondary) | Will be estimated using the method of Gooley et al. | Up to 100 days post-HCT | |
Secondary | Incidence of acute graft-versus-host disease | Will be estimated using the method of Gooley et al. | Up to 100 days post-HCT | |
Secondary | Incidence of chronic graft-versus-host disease | Will be estimated using the method of Gooley et al. | Up to 1 year post-HCT | |
Secondary | Incidence of chronic graft-versus-host disease | Will be estimated using the method of Gooley et al. | Up to 2 years post-HCT | |
Secondary | Incidence of grade II or greater organ toxicity | Will be reported as counts with percentages. | Up to 100 days post-HCT | |
Secondary | Incidence of hepatic sinusoidal obstruction syndrome | Will be reported as counts with percentages. | Up to 100 days post-HCT | |
Secondary | Incidence of central nervous system toxicities including posterior reversible encephalopathy syndrome | Will be reported as counts with percentages. | Up to 100 days post-HCT | |
Secondary | Incidence of infectious complications | Will be reported as counts with percentages. | Up to 100 days post-HCT |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT02227472 -
Working Memory and School Readiness in Preschool-Aged Children With Sickle Cell Disease
|
||
Recruiting |
NCT06301893 -
Uganda Sickle Surveillance Study (US-3)
|
||
Recruiting |
NCT04398628 -
ATHN Transcends: A Natural History Study of Non-Neoplastic Hematologic Disorders
|
||
Completed |
NCT02522104 -
Evaluation of the Impact of Renal Function on the Pharmacokinetics of SIKLOS ® (DARH)
|
Phase 4 | |
Recruiting |
NCT04688411 -
An mHealth Strategy to Improve Medication Adherence in Adolescents With Sickle Cell Disease
|
N/A | |
Terminated |
NCT03615924 -
Effect of Ticagrelor vs. Placebo in the Reduction of Vaso-occlusive Crises in Pediatric Patients With Sickle Cell Disease
|
Phase 3 | |
Not yet recruiting |
NCT06300723 -
Clinical Study of BRL-101 in Severe SCD
|
N/A | |
Recruiting |
NCT03937817 -
Collection of Human Biospecimens for Basic and Clinical Research Into Globin Variants
|
||
Completed |
NCT04134299 -
To Assess Safety, Tolerability and Physiological Effects on Structure and Function of AXA4010 in Subjects With Sickle Cell Disease
|
N/A | |
Completed |
NCT04917783 -
Health Literacy - Neurocognitive Screening in Pediatric SCD
|
N/A | |
Completed |
NCT02580565 -
Prevalence of Problematic Use of Equimolar Mixture of Oxygen and Nitrous Oxide and Analgesics in the Sickle-cell Disease
|
||
Recruiting |
NCT04754711 -
Interest of Nutritional Care of Children With Sickle Cell Disease on Bone Mineral Density and Body Composition
|
N/A | |
Completed |
NCT04388241 -
Preliminary Feasibility and Efficacy of Behavioral Intervention to Reduce Pain-Related Disability in Pediatric SCD
|
N/A | |
Recruiting |
NCT05431088 -
A Phase 2/3 Study in Adult and Pediatric Participants With SCD
|
Phase 2/Phase 3 | |
Completed |
NCT01158794 -
Genes Influencing Iron Overload State
|
||
Recruiting |
NCT03027258 -
Point-of-Delivery Prenatal Test Results Through mHealth to Improve Birth Outcome
|
N/A | |
Withdrawn |
NCT02960503 -
Macrolide Therapy to Improve Forced Expiratory Volume in 1 Second in Adults With Sickle Cell Disease
|
Phase 1/Phase 2 | |
Completed |
NCT02567695 -
A Single-Dose Relative Bioavailability Study Of GBT440 300 mg Capsules in Healthy Subjects
|
Phase 1 | |
Not yet recruiting |
NCT02525107 -
Prevention of Vaso-occlusive Painful Crisis by Using Omega-3 Fatty Acid Supplements
|
Phase 3 | |
Completed |
NCT02620488 -
A Brief Laboratory-Based Hypnosis Session for Pain in Sickle Cell Disease
|
N/A |